Article
Medicine, Research & Experimental
Dan Huang, Guohuan Sun, Xiaoxin Hao, Xiaoxiao He, Zhaofeng Zheng, Chiqi Chen, Zhuo Yu, Li Xie, Shihui Ma, Ligen Liu, Bo O. Zhou, Hui Cheng, Junke Zheng, Tao Cheng
Summary: Reducing SEV production from endothelial cells significantly delays leukemia progression, without affecting normal hematopoiesis. These findings reveal a role of niche-specific SEVs in cancer development and suggest that targeting ANGPTL2-SEVs released from endothelial cells may be a potential strategy to interfere with certain types of AML.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Oncology
Koshiro Fukuda, Hiroki Osumi, Koichiro Yoshino, Izuma Nakayama, Shota Fukuoka, Mariko Ogura, Takeru Wakatsuki, Akira Ooki, Daisuke Takahari, Keisho Chin, Kensei Yamaguchi, Eiji Shinozaki
Summary: This exploratory study aimed to evaluate the impact of single-organ pulmonary metastases on progression-free survival and overall survival in patients with metastatic colorectal cancer. The results showed that patients with single-organ pulmonary metastasis had higher disease control rates, longer progression-free survival, and overall survival compared to patients with other forms of metastatic colorectal cancer.
Article
Oncology
Yoshitaka Saito, Yoh Takekuma, Yoshito Komatsu, Mitsuru Sugawara
Summary: This study retrospectively assessed 100 patients with metastatic colorectal cancer who received regorafenib treatment. The results showed that patients who developed grade 3 or higher hypertension had significantly longer progression-free survival. However, there was no significant difference in overall survival and disease control rate between the groups.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Malin Ljunggren, Caroline E. Weibull, Gabriella Palmer, Emerik Osterlund, Bengt Glimelius, Anna Martling, Caroline Nordenvall
Summary: This population-based study found that women with synchronous metastatic colorectal cancer (mCRC) were less likely to receive metastatic surgery and had slightly higher all-cause mortality compared to men.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Oncology
Premila D. Leiphrakpam, Audrey J. Lazenby, Lynette M. Smith, Michael G. Brattain, Chandrakanth Are
Summary: The study revealed a correlation between high stathmin expression and CRC metastasis as well as worse prognosis, along with increased cell proliferation. These findings suggest stathmin as a potential marker for increased risk and treatment in CRC patients.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Maria I. Aroca-Siendones, Sara Moreno-SanJuan, Jose D. Puentes-Pardo, Michela Verbeni, Javier Arnedo, Julia Escudero-Feliu, Maria Garcia-Costela, Adelina Garcia-Robles, Angel Carazo, Josefa Leon
Summary: Low expression of PER2 and BMAL1 is associated with metastasis at the time of CRC diagnosis, high expression of CRY1 is an independent prognostic factor for metastasis development, and high expression of NR1D2 is an independent prognostic factor for local recurrence development. Patients with low BMAL1 expression and high CRY1 expression show lower overall survival and disease-free survival at five years.
Article
Oncology
Shun Yamamoto, Kengo Nagashima, Takeshi Kawakami, Seiichiro Mitani, Masato Komoda, Yasushi Tsuji, Naoki Izawa, Kentaro Kawakami, Yoshiyuki Yamamoto, Akitaka Makiyama, Kentaro Yamazaki, Toshiki Masuishi, Taito Esaki, Takako Eguchi Nakajima, Hiroyuki Okuda, Toshikazu Moriwaki, Narikazu Boku
Summary: This study found that in mCRC patients, those who experienced early progression in first-line chemotherapy showed poor clinical outcomes with second-line chemotherapy regardless of the use of anti-angiogenic agents.
Article
Oncology
Erin L. Van Blarigan, Chao Ma, Fang-Shu Ou, Tiffany M. Bainter, Alan P. Venook, Kimmie Ng, Donna Niedzwiecki, Edward Giovannucci, Heinz-Josef Lenz, Blase N. Polite, Howard S. Hochster, Richard M. Goldberg, Robert J. Mayer, Charles D. Blanke, Eileen M. O'Reilly, Kristen K. Ciombor, Jeffrey A. Meyerhardt
Summary: This study found that moderate or higher intake of vegetable fat may be associated with a lower risk of mortality and cancer progression among patients with metastatic colorectal cancer.
INTERNATIONAL JOURNAL OF CANCER
(2023)
Article
Multidisciplinary Sciences
Jia-Jun Li, Jin-Hong Wang, Tian Tian, Jia Liu, Yong-Qiang Zheng, Hai-Yu Mo, Hui Sheng, Yan-Xing Chen, Qi-Nian Wu, Yi Han, Kun Liao, Yi-Qian Pan, Zhao-Lei Zeng, Ze-Xian Liu, Wei Yang, Rui-Hua Xu, Huai-Qiang Ju
Summary: This study identifies the critical role of FGL1 in promoting liver metastases in colorectal cancer and uncovers its regulatory mechanism. Inhibiting the TAM-OTUD1-FGL1 axis can inhibit metastatic tumor progression and synergize with immune checkpoint blockade therapy. High plasma FGL1 levels predict poor outcomes and reduced benefit from immune checkpoint blockade therapy.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, Research & Experimental
Barbara Chiavarina, Brunella Costanza, Roberto Ronca, Arnaud Blomme, Sara Rezzola, Paola Chiodelli, Ambre Giguelay, Guillame Belthier, Gilles Doumont, Gaetan Van Simaeys, Simon Lacroix, Takehiko Yokobori, Bilguun Erkhem-Ochir, Patrick Balaguer, Vincent Cavailles, Eric Fabbrizio, Emmanuel Di Valentin, Stephanie Gofflot, Olivier Detry, Guy Jerusalem, Serge Goldman, Philippe Delvenne, Akeila Bellahcene, Julie Pannequin, Vincent Castronovo, Andrei Turtoi
Summary: Colorectal cancer (CRC) cells have the ability to directly respond to TGF beta, affecting their metastatic potential and angiogenesis. Targeting proteins downstream of activated TGF beta, such as TGFBI, may provide novel diagnostic and therapeutic targets for more specific anti-metastatic therapies.
Article
Oncology
Premila D. Leiphrakpam, Audrey J. Lazenby, Lynette M. Smith, Michael G. Brattain, Jennifer D. Black, Jing Wang, Chandrakanth Are
Summary: High expression of PRL3 in colorectal cancer is associated with tumor progression and metastasis, with every one unit increase contributing to an increase in the rate of death by 1%-1.7%. PRL3 expression is significantly higher in liver metastases compared with primary tumors and shows a significant positive correlation with the expression level of p-Akt S473.
JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Medicine, Research & Experimental
Peng Xiang, Qingqiu Chen, Le Chen, Jin Lei, Zhiyi Yuan, Hui Hu, Yining Lu, Xianmin Wang, Tingting Wang, Ruihong Yu, Wanping Zhang, Jun Zhang, Chao Yu, Limei Ma
Summary: This study reveals that the metabolite Neu5Ac may regulate the progression of atherosclerosis (AS) by affecting endothelial cell (EC) function. The results show that Neu5Ac exacerbates plaque formation and increases lipid levels in plasma, and triggers EC inflammatory injury to promote AS development. Further mechanistic studies demonstrate that Neu5Ac facilitates the binding of SLC3A2 to ubiquitin, leading to the accumulation of lipid peroxidation in ECs. Additionally, mitochondrial dysfunction is also involved in EC injury after Neu5Ac treatment. The study suggests that inhibiting endothelial ferroptosis may be a novel therapeutic strategy for premature AS.
Article
Oncology
Katsuji Sawai, Takanori Goi, Youhei Kimura, Kenji Koneri
Summary: This study investigated the relationship between oxidative stress and treatment response in patients with metastatic colorectal cancer. The rate of change in reactive oxygen metabolite derivatives (d-ROM) was found to be a predictor of treatment response. This research is important for understanding the mechanisms of colorectal cancer treatment and guiding clinical practice.
Article
Oncology
Shenshen Wu, Xi Yang, Weiyan Tang, Giuseppe Familiari, Michela Relucenti, Michael Aschner, Xiaobo Li, Rui Chen
Summary: Recent studies have found an association between the PVT1 rs2278176 CT/TT genotypes and a better chemotherapy response, overall survival, and progression-free survival in metastatic colorectal cancer patients. In vivo experiments showed that the rs2278176 C to T mutation inhibited tumor growth and increased apoptosis in colorectal cancer cells treated with 5-Fu. Functional studies revealed that the rs2278176 C to T mutation altered the binding site for hsa-miR-297, leading to downregulation of GSTA2 expression. High GSTA2 expression predicted poor clinical outcomes in metastatic colorectal cancer treated with FOLFOX.
FRONTIERS IN ONCOLOGY
(2022)
Article
Multidisciplinary Sciences
Jiawei Zhou, Amber Cipriani, Yutong Liu, Gang Fang, Quefeng Li, Yanguang Cao
Summary: This study investigates the heterogeneity of lesion-specific response and progression in metastatic colorectal cancer (mCRC) patients. The authors find that the sequence of progression at the organ level is associated with long-term survival.
NATURE COMMUNICATIONS
(2023)
Article
Oncology
Diego de Miguel-Perez, Edward M. Pickering, Umberto Malapelle, William Grier, Francesco Pepe, Pasquale Pisapia, Gianluca Russo, Joseph A. Pinto, Alessandro Russo, Giancarlo Troncone, Melissa J. Culligan, Katherine A. Scilla, Ranee Mehra, Pranshu Mohindra, Oscar Arrieta, Andres F. Cardona, Marzia Del Re, Ashutosh Sachdeva, Fred R. Hirsch, Andrea Wolf, Joseph S. Friedberg, Christian Rolfo
Summary: In this study, genetic alterations in resectable pleural mesothelioma tissues and blood samples were analyzed, and it was found that high tissue tumor mutational burden, tissue median minor allele frequency, blood tumor mutational burden, and specific mutations were correlated with outcomes in patients with resected PM. These findings suggest that molecular profiling could help identify longer survivors in patients with resected PM.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Davide Melisi, Camilla Zecchetto, Valeria Merz, Giuseppe Malleo, Luca Landoni, Alberto Quinzii, Simona Casalino, Federica Fazzini, Marina Gaule, Camilla Pesoni, Luca Casetti, Alessandro Esposito, Giovanni Marchegiani, Cristiana Piazzola, Mirko D'Onofrio, Riccardo de Robertis, Armando Gabbrielli, Laura Bernardoni, Stefano F. Crino, Silvia Pietrobono, Claudio Luchini, Camillo Aliberti, Guido Martignoni, Stefano Milleri, Giovanni Butturini, Aldo Scarpa, Roberto Salvia, Claudio Bassi
Summary: This study evaluated the safety and activity of liposomal irinotecan in the perioperative treatment of resectable pancreatic ductal adenocarcinoma (rPDAC) patients. The results showed that NALIRIFOX has manageable and active outcomes, and should be further investigated in randomized trials comparing it to standard upfront surgery followed by adjuvant therapy.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Eric Jonasch, Todd M. Bauer, Kyriakos P. Papadopoulos, Elizabeth R. Plimack, Jaime R. Merchan, David F. Mcdermott, M. Dror Michaelson, Leonard J. Appleman, Ananya Roy, Rodolfo F. Perini, Yanfang Liu, Toni K. Choueiri
Summary: After a median follow-up of 41.2 months, belzutifan monotherapy demonstrated durable antitumor activity in patients with advanced ccRCC and acceptable safety.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Patricia A. H. Hamers, Geraldine R. Vink, Marloes A. G. Elferink, Leon M. G. Moons, Cornelis J. A. Punt, Anne M. May, Miriam Koopman
Summary: Screen-detection of the primary tumor is associated with longer overall survival after metachronous metastasis.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Camilla Nero, Nicolo Bizzarri, Stefano Di Berardino, Francesca Sillano, Giuseppe Vizzielli, Francesco Cosentino, Virginia Vargiu, Pierandrea De Iaco, Anna Myriam Perrone, Enrico Vizza, Benito Chiofalo, Stefano Uccella, Fabio Ghezzi, Luigi Carlo Turco, Giacomo Corrado, Diana Giannarelli, Tina Pasciuto, Gian Franco Zannoni, Anna Fagotti, Giovanni Scambia
Summary: This study evaluates the sensitivity and specificity of sentinel-lymph-node mapping compared to systematic lymphadenectomy in detecting lymph node metastasis in early stage ovarian cancer. The results show that sentinel-lymph-node mapping did not reach the expected sensitivity, but ultra-staging protocol improved the accuracy of diagnosis for patients.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Adriana Hepner, Judith M. Versluis, Roslyn Wallace, Clara Allayous, Lauren Julia Brown, Claudia Trojanielloh, Camille Lea Gerardi, Yanina J. L. Jansenj, Prachi Bhave, Bart Neyns, Andrew Haydon, Olivier Michielin, Joanna Manganan Oliver Klein, Alexander N. Shoushtari, Allison Betof Warner, Paolo Antonio Ascierto, Jennifer Leigh McQuade, Matteo S. Carlino, Lisa Zimmer, Celeste Lebbe, Douglas B. Johnson, Shahneen Sandhu, Victoria Atkinson, Christian U. Blank, Serigne N. Lo, Georgina V. Long, Alexander M. Menzies
Summary: Acquired resistance to PD-1 therapy in melanoma is mainly oligometastatic, and patients may have a favorable survival outcome following salvage treatment.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Savannah Roy, Stephanie Lakritz, Anna R. Schreiber, Elizabeth Molina Kuna, Cathy J. Bradley, Lavanya Kondapalli, Jennifer R. Diamond
Summary: This study evaluates major adverse cardiovascular events (MACE) in older women with TNBC treated with anthracycline and taxane-based chemotherapy (ATAX) compared to taxane-based chemotherapy (TAX). The results show that ATAX does not increase the risk of MACE and there is no difference in survival between patients who received TAX and ATAX.
EUROPEAN JOURNAL OF CANCER
(2024)
Letter
Oncology
Pei-Chun Weng, Yau-Li Huang, Chun-Yu Cheng
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Philipp Jansen, Jean Le 'Clerc Arrastia, Daniel Otero Baguer, Maximilian Schmidt, Jennifer Landsberg, Joerg Wenzel, Michael Emberger, Dirk Schadendorf, Eva Hadaschik, Peter Maass, Klaus Georg Griewank
Summary: This study highlights the enormous potential of artificial intelligence in pathology, showing that it can aid in the identification of rare cutaneous adnexal tumors and potentially become a standard tool in routine diagnostics.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Casper W. F. van Eijck, Gaby Strijk, Eveline E. Vietscha, Fleur van der Sijde, Maaike Verheij, Dana A. M. Mustafa, Madelief Vinkc, Joachim G. J. V. Aerts, Casper H. J. van Eijck, Marcella Willemsen
Summary: The study reveals that FOLFIRINOX has immunomodulatory effects, suggesting its potential in immune-based combination therapies for pancreatic cancer. Additionally, certain plasma proteins hold promise as circulating predictive biomarkers for early prediction of FOLFIRINOX response in patients with pancreatic cancer.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Marwan Fakih, Chongkai Wang, Jaideep Sandhu, Jian Ye, Colt Egelston, Xiaochen Li
Summary: This study explores the impact of metastatic sites on treatment outcomes for chemotherapy-refractory colorectal cancer patients. It found that patients with liver or peritoneal metastases had poor treatment outcomes, while those with lung-only metastases showed significant response. The presence of concurrent lymph node or other extrahepatic metastatic disease diminished treatment response in patients with lung metastases. Future checkpoint inhibitor trials should stratify patients based on metastatic locations.
EUROPEAN JOURNAL OF CANCER
(2024)
Article
Oncology
Georgios Christos Tsiatsianis, Candace S. Y. Chan, Ioannis Mouratidis, Nikol Chantzi, Anna Maria Tsiatsiani, Nelson S. Yee, Apostolos Zaravinos, Verena Kantere, Ilias Georgakopoulos-Soares
Summary: The study reveals that nullpeptides can serve as biomarkers for cancer detection and treatment, particularly in highly recurrent cancer patients. These nullpeptides primarily occur in highly expressed genes, particularly in specific loci of oncogenes and tumor suppressors. Recurrent nullpeptides are more likely to be found in neoantigens, which play a significant role in immunotherapy.
EUROPEAN JOURNAL OF CANCER
(2024)